公开(公告)号：EP3251675A1

公开(公告)日：2017-12-06

申请号：EP16742632.9

申请日：2016-01-28

申请人： Shanton Pharma Co., Ltd.

发明人： ZHANG, Qian ,  HUANG, Zhenhua ,  LIU, Jinrong ,  CHI, Shuangshuang

IPC分类号： A61K31/522 ,  C07D473/06 ,  C07D473/08 ,  A61P13/04 ,  A61P19/06 ,  A61P29/00 ,  A61P19/02 ,  A61P13/12

CPC分类号： A61K31/522 ,  A61K31/4188 ,  A61K2300/00 ,  C07D473/04 ,  C07D473/06 ,  C07D473/08 ,  C07D487/04

摘要： The present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in reducing uric acid level, preventing or reducing inflammations, and preventing or treating uratic or gouty diseases. In particular, the present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in the manufacture of a medicament for the treatment or prevention of hyperuricemia, gout, gouty inflammations, pain and uric acid nephropathy.

R 1 represents hydrogen, C 1-4 alkyl or the like. R 2 represents C 1-10 alkyl or the like. R 3 represents halogen or the like.

摘要翻译： 本发明涉及式（I）化合物，其药学上可接受的盐，其溶剂化物或包含其的药物组合物在降低尿酸水平，预防或减轻炎症，以及预防或治疗尿酸或 痛风疾病。 特别地，本发明涉及式（I）化合物，其药学上可接受的盐，其溶剂合物或含有其的药物组合物在制备用于治疗或预防高尿酸血症的药物中的用途， 痛风，痛风炎症，疼痛和尿酸肾病。 R1代表氢，C1-4烷基等。 R2代表C1-10烷基等。 R3代表卤素等。

公开(公告)号：EP3251675A4

公开(公告)日：2018-06-20

申请号：EP16742632

申请日：2016-01-28

申请人： SHANTON PHARMA CO LTD

发明人： ZHANG QIAN ,  HUANG ZHENHUA ,  LIU JINRONG ,  CHI SHUANGSHUANG

IPC分类号： C07D473/08 ,  A61K31/522 ,  A61P13/04 ,  A61P13/12 ,  A61P19/02 ,  A61P19/06 ,  A61P29/00 ,  C07D473/06

CPC分类号： A61K31/522 ,  A61K31/4188 ,  A61K2300/00 ,  C07D473/04 ,  C07D473/06 ,  C07D473/08 ,  C07D487/04

摘要： The present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in reducing uric acid level, preventing or reducing inflammations, and preventing or treating uratic or gouty diseases. In particular, the present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in the manufacture of a medicament for the treatment or prevention of hyperuricemia, gout, gouty inflammations, pain and uric acid nephropathy. R 1 represents hydrogen, C 1-4 alkyl or the like. R 2 represents C 1-10 alkyl or the like. R 3 represents halogen or the like.